Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
246 studies found for:    "Adenocarcinoma of lung"
Show Display Options
Download search resultsDownload the search results for:
"Adenocarcinoma of lung" (246 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
Conditions: Adenocarcinoma of Lung Stage IIIB;   Adenocarcinoma of Lung Stage IV
Intervention: Drug: NOV120101 (Poziotinib)
2 Unknown  Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention:
3 Recruiting Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases
Conditions: Lung Adenocarcinoma;   Brain Metastases
Interventions: Drug: erlotinib;   Drug: pemetrexed;   Drug: cisplatin
4 Recruiting Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy
Condition: Lung Adenocarcinoma
Intervention: Other: CT, PET, copy number alteration
5 Recruiting Telomere Biology in Early Adenocarcinoma of the Lung
Conditions: Adenocarcinoma of the Lung;   Adenocarcinoma, Bronchiolo-Alveolar
Intervention:
6 Completed Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung
Conditions: Non-small-cell Lung Cancer;   Squamous Cell Carcinoma;   Adenocarcinoma of the Lung
Interventions: Drug: AXL1717;   Drug: Docetaxel
7 Unknown  The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar
Condition: Advanced Primary Lung Adenocarcinoma
Intervention: Drug: endostar
8 Not yet recruiting Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas
Conditions: Lung Adenocarcinoma;   Breast Adenocarcinoma;   Pancreatic Ductal Adenocarcinoma
Intervention: Other: their will be no intervention in any of the groups, the study is retrospective
9 Not yet recruiting Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion
Conditions: Non-small Cell Lung Cancer Stage I;   Lung Adenocarcinoma
Interventions: Procedure: patients undergo cVATS segmentectomy;   Procedure: Patients undergo cVATS lobectomy
10 Completed Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Condition: Lung Adenocarcinoma
Intervention: Drug: erlotinib along with cetuximab
11 Not yet recruiting A Study Examining Maintenance Avastin Monotherapy in Patients With Advanced Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention:
12 Completed Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)
Condition: Adenocarcinoma of the Lung
Interventions: Drug: Vintafolide;   Drug: Etarfolatide
13 Completed A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung
Condition: Adenocarcinoma of the Lung
Interventions: Biological: farletuzumab;   Other: Placebo;   Drug: Platinum Containing Doublet
14 Recruiting Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas
Condition: Stage IV Lung Adenocarcinoma
Interventions: Drug: Certolizumab;   Drug: cisplatin;   Drug: pemetrexed
15 Unknown  Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention:
16 Recruiting Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
Condition: KIF5B-RET-Positive Adenocarcinoma of the Lung
Intervention: Drug: Lenvatinib
17 Recruiting Comparative Study of Chemoradiation and Sequential Chemoradiation About Lung Adenocarcinoma Patients With Postoperative in pN2
Condition: Lung Adenocarcinoma Patients With Postoperative in pN2
Intervention: Radiation: intensity-modulated radiation
18 Recruiting A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.
Conditions: Carcinoma, Non-Small-Cell Lung;   Lung Adenocarcinoma
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Bevacizumab;   Drug: Metformin
19 Active, not recruiting Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: Hsp90 inhibitor AUY922;   Other: laboratory biomarker analysis;   Procedure: needle biopsy;   Genetic: mutation analysis;   Other: pharmacological study
20 Completed Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature
Conditions: Pneumonic-type Adenocarcinoma (P-ADC);   Lung Adenocarcinoma With Bronchiolo-alveolar Feature
Intervention: Drug: Gefitinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years